Current aspects of pimecrolimus application in clinical practice

Cover Page

Cite item

Full Text

Abstract

Modern aspects of patogenetic conception of neurogenic inflammation in immune associated dermatoses are presented in the article. On the basis of literature data and own experience important aspects of pimecrolimus application in atopic dermatitis and other dermatoses are reviewed.

About the authors

A N Lvov

Moscow Scientific and Practical Center of Dermatology, Venereology and Cosmetology of Moscow City Health Department

Email: alvov@mail.ru
доктор медицинских наук, профессор. Руководитель отдела клинической дерматовенерологии и косметологии

References

  1. Eyeric K., Eyerich S., Biedermann T. The Multi-Modal Immune Pathogenesis of Atopic Eczema. Trends in Immunology. 2015; 36(12). http://dx.doi.org/10.1016Xj.it.2015.10.006.
  2. Murota H., Katayama I. Exacerbating factors of itch in atopic dermatitis. Allergol Int. 2017;66(1):8-13. DOI: 10.1016/j. alit.2016.10.005.
  3. Mollanazar NK, Smith PK, Yosipovitch G. Mediators of Chronic Pruritus in Atopic Dermatitis: Getting the Itch Out? Clinic Rev Allerg Immunol. 2016;51:263-292. DOI: 10.1007/ s12016-015-8488-5.
  4. Ru-Rong Л. Neuroimmune interactions in itch: Do chronic itch, chronic pain, and chronic cough share similar mechanisms? Pulmonary Pharmacology & Therapeutics. 2015;35;81-86. http://dx.doi.org/10.1016/j.pupt.2015.09.001.
  5. Wollenberg А., Barbarot S., Bieber T. et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. JEADV. 2018;32:850-878.
  6. Монахов КН, Очеленко С.А. Эффективность и безопасность применения пимекролимуса при атопическом дерматите у детей. Вопросы современной педиатрии. 2008;7(6):141-144
  7. Siegfried EC, Jaworski JC, Hebert AA. Topical Calcineurin Inhibitors and Lymphoma Risk: Evidence Update with Implications for Daily Practice. Am J. Clin Dermatol. 2013;14:163-178. doi: 10.1007/s40257-013-0020-1.
  8. Eichenfield LF, Tom WL, Berger TG et al. Guidelines of care for the management of atopic dermatitis. J. Am Acad Dermatol. 2014;71(1):116-132. http://dx.doi.org/10.1016/j. jaad.2014.03.023.
  9. Weidinger S., Baurecht H., Schmitt J. A 5-year randomized trial on the safety and efficacy of pimecrolimus in atopic dermatitis: a critical appraisal. Br J. Dermatol. 2017;177(4):999-1003. doi: 10.1111/bjd.15827.
  10. Sigurgeirsson B., Boznanski A., Todd G. et al. Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial Pediatrics. 2015;135;Issue 4:597-606.
  11. Huang Ch, Sheng Y. Pimecrolimus Cream 1% in the Management of Atopic Dermatitis in Pediatric Patients: A Meta-Analysis. PLOS ONE. 2014; 1. https://doi.org/10.1371/ journal.pone.0093095.
  12. Эфендиева КЕ, Левина ЮГ, Намазова-Баранова Л.С. Эффективность и безопасность 1% крема пимекролимуса у детей с атопическим дерматитом. Педиатрическая дерматология. 2009;6(1): 30-36
  13. Jacobi A., Braeutigam M., Mahler V. Pimecrolimus 1% Cream in the Treatment of Facial Psoriasis: A 16-Week Open-Label Study. Dermatology. 2008;216:133-136.
  14. Kalb RE, Bagel J., Korman NJ. Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation. JAAD. 2009;60;Issue 1:120-124.
  15. Dinh H., Purcell SM, Chung C. et al. Pediatric Lichen Sclerosus: A Review of the Literature and Management Recommendations. J. Clin Aesthet Dermatol. 2016;9(9):49-54.
  16. Goldstein AT, Marinoff SC, Christopher K. Pimecrolimus for the treatment of vulvar lichen sclerosus in a premenarchal girl. J. Pediatr Adolesc Gynecol. 2004;17(1):35-37.
  17. Oskay T., Sezer HK, Genç C. et al. Pimecrolimus 1% cream in the treatment of vulvar lichen sclerosus in postmenopausal women. Int J. Dermatol. 2007;46(5):527-532.
  18. Sheinis M., Selk А. Development of the Adult Vulvar Lichen Sclerosus Severity Scale - A Delphi Consensus Exercise for Item Generation J. Low Genit Tract Dis. 2018;22(1):66-73.
  19. Koca R., Altinyazar H. A comparison of metronidazole 1% cream and pimecrolimus 1% cream in the treatment of patients with papulopustular rosacea: A randomized open-label clinical trial. Clinical and Experimental Dermatology. 2009;35(3):251-256.
  20. Kim MB, Kim G., Park HJ. Pimecrolimus 1% cream for the treatment of rosacea. J. Dermatol. 2011;38(12):1135-1139. doi: 10.1111/j.1346-8138.2011.01223.x.
  21. Kim G, Del Rosso J. Topical Pimecrolimus 1% Cream in the Treatment of Seborrheic Dermatitis. J Clin Aesthet Dermatol. 2013;6(2):29-35.
  22. Tatlican S, Eren C, Oktay B. Experience with repetitive use of pimecrolimus: exploring the effective and safe use in the treatment of relapsing seborrheic dermatitis. J Dermatolog Treat. 2010;21(2):83-85. doi: 10.1080/09546630902882055.
  23. Khondker L, Wahab MA, Khan SI. Efficacy oftopical application of Pimecrolimus cream in the treatment of discoid lupus erythematosus. Mymensingh Med J. 2012;21(2):259-264.
  24. Lampropoulos CD. Topical calcineurin inhibitors in systemic lupus erythematosus. Ther Clin Risk Manag. 2010;6:95-101.
  25. Seirafi H, Farnaghi F, Firooz A et al. Pimecrolimus cream in repigmentation ofvitiligo. Dermatology. 2007;214(3):253-259.
  26. Woo-Haing Shim, Sung-Won Suh, Seung-Wook Jwa. A Pilot Study of 1% Pimecrolimus Cream for the Treatment of Childhood Segmental Vitiligo. Ann Dermatol. 2013;25(2):168-172.
  27. Gianfaldoni S, Wollina U, Tchernev G et al. Vitiligo in Children: A Review of Conventional Treatments Open Access Maced. J Med Sci. 2018;6(1):213-217.
  28. Esfandiarpour I, Ekhlasi A, Farajzadeh S et al. The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. J Dermatol Treat. 2009;20:14-18.
  29. Lonsdale-Eccles A, Velangi S. Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series. Br J Dermatol. 2005;153(2):390-394.
  30. Scheer M, Kawari-Mahmoodi N, Neugebauer J. Pimecrolimus (Elidel) for therapy of lichen ruber mucosae. Mund Kiefer Gesichtschir. 2006;10(6):403-407.

Copyright (c) 2019 Pharmarus Print Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies